Evidence map›Paper›PMID 42190056›Full record

ArticleCardiovascular research2026

Targeting RUNX1 protects against diastolic dysfunction in a two-hit mouse model of heart failure with preserved ejection fraction.

Ali Ali Mohamed Elbassioni, Anmar A Raheem, Jian Song, Alexander S Johnston, Cara Trivett, Hong Lin, Haobo Zhang, Ashley Bradley, Erin Higgins, Cameron R Thomson and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

Ali Ali Mohamed ElbassioniSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.ORCID 0000-0003-2641-2460
Anmar A RaheemSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.ORCID 0000-0002-6233-6218
Jian SongSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Alexander S JohnstonSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Cara TrivettSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Hong LinSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Haobo ZhangSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Ashley BradleySchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Erin HigginsSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Cameron R ThomsonSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Leanne MooneySchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Yen Chin KoaySchool of Medical Sciences, The University of Sydney, Sydney, New South Wales, Australia.
Dylan O'TooleSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Pawel HerzykSchool of Molecular Biosciences, University of Glasgow, Glasgow, UK.
Colin NixonCancer Research UK Scotland Institute, Glasgow, UK.
Karen BlythCancer Research UK Scotland Institute, Glasgow, UK.
Mark HughesCancer Research UK Scotland Institute, Glasgow, UK.
Nawwar Al-AttarSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
John F O'SullivanSchool of Medical Sciences, The University of Sydney, Sydney, New South Wales, Australia.
Ninian N LangSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.ORCID 0000-0001-8441-6887
Colin BerrySchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.ORCID 0000-0002-4547-8636
Thomas BraunDepartment of Cardiac Development and Remodelling, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.ORCID 0000-0002-6165-4804
Gabriele G SchiattarellaDeutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Max Rubner Center for Cardiovascular Metabolic Renal Research (MRC), Charité-Universitätsmedizin Berlin, Germany, Berlin, Germany.
Mauro GiaccaDepartment of Cardiothoracic Surgery, Suez Canal University, Ismailia, Egypt.ORCID 0000-0003-2927-7225
Martin W McBrideSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Stuart A NicklinSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Ewan R CameronSchool of Biodiversity One Health and Veterinary Medicine, University of Glasgow, Glasgow, UK.
Christopher M LoughreySchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.ORCID 0000-0003-1297-9159
Eilidh A MacDonaldSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.ORCID 0000-0002-7771-754X

Funding

BHF programme RG/20/6/35095British Heart Foundation RE/18/6/34217
6 · The paper itself

Abstract

aimsHeart failure with preserved ejection fraction (HFpEF) continues to increase in prevalence and has limited treatment options. HFpEF is a systemic condition with a broad phenotype including diastolic dysfunction, pulmonary oedema, exercise intolerance, and left ventricular hypertrophy, collectively resulting in enhanced morbidity and mortality. The transcription factor RUNX1 has recently been identified as a mediator of pathological changes in multiple cardiac diseases; however, its role in HFpEF remained unknown. METHODS AND

resultsHere, we show that inhibition of Runx1 limits adverse cardiac remodelling in a mouse model of HFpEF. Cardiomyocyte-specific tamoxifen-inducible Runx1-deficient mice with HFpEF are protected, with preservation of diastolic function, and attenuation of pulmonary oedema, exercise intolerance, and hypertrophy. Furthermore, targeting Runx1 in HFpEF by using gene transfer or small-molecule inhibitor Ro5-3335 improves diastolic function and reduces pulmonary oedema, both in female and male mice.

conclusionOverall, this work enhances our understanding of RUNX1 in cardiac disease and presents a novel translational target for the treatment of HFpEF.

Indexed as

Core Binding Factor Alpha 2 SubunitHeart FailureHeart Failure, DiastolicMyocytes, CardiacStroke VolumeVentricular Dysfunction, LeftVentricular Function, LeftAnimalsDiastoleDisease Models, AnimalExercise ToleranceFemaleHypertrophy, Left VentricularMaleMice, Inbred C57BLMice, KnockoutCore Binding Factor Alpha 2 SubunitRunx1 protein, mouseDiastolic dysfunctionExercise intoleranceHeart failure with preserved ejection fractionHypertrophyMetabolic heart failurePulmonary oedema

Identifiers

PMID42190056
PMCPMC13355837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.